UCR 280: Testosterone Pellet Denials, Secondary Payer Prior Auths, and Urology Risk Assessments
Failed to add items
Add to Cart failed.
Add to Wish List failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
UCR 280: Testosterone Pellet Denials, Secondary Payer Prior Auths, and Urology Risk Assessments
-
Narrated by:
-
By:
March 13, 2026
In this episode, Scott, Mark, and Dr. Ray Painter tackle three emerging reimbursement challenges affecting urology practices: widespread denials for testosterone pellet (Testopel®) therapy, the growing trend of secondary payers requiring prior authorization for high-cost drugs, and whether urology questionnaires qualify as billable health risk assessments.
PRS Coding and Reimbursement Hub
Access the Hub
Botox LCD Alert
Download the Alert
Free In-Office Prostate Biopsy Calculator (Suppoted by UC-Care)
Download Now
PRS Coding Courses
For Urologist
For APPs
For Coders, Billers, and Admins
Join the Urology Pharma and Tech Pioneer Group
Empowering urology practices to adopt new technology faster by providing clear reimbursement strategies—ensuring the practice gets paid and patients benefit sooner.
https://www.prsnetwork.com/joinuptp
Click Here to Start Your Free Trial of AUACodingToday.com
The Thriving Urology Practice Facebook group.
The Thriving Urology Practice Facebook Group link to join:
https://www.facebook.com/groups/ThrivingPractice/